SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Value Investing
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Michael Burry who wrote (3172)2/10/1998 1:59:00 PM
From: Wallace Rivers  Read Replies (1) of 78595
 
I have mentioned this to the thread before at lower prices, but I would like some input in light of the recent acquisition announcement of Arbor Drugs (ARBR).
The stock of Phar-Mor (PMOR) seems significantly value when one compares it to Arbor in certain key statistical ratios:

P/B ARBR 3.9 PMOR 1.3
P/S ARBR 1.07 PMOR .1
CR ARBR 2.3/1 PMOR 2.9/1

PE ARBR 30 PMOR NM*
*PMOR reported its first profitable Q last report, I believe the company can earn .60 this year.
PMOR certainly has significantly more debt on the books than ARBR. It also has more cash assets, as well.
Both companies have approximately $1 bil. in sales.
It could be argued that ARBR is a much more seasoned company, dominating its particular market (Detroit), while PMOR has the stigma of a company emerging from a scandalous past.
That being said, I still don't think that PMOR should trade at such an extreme discount to ARBR.

AOL valuation still makes me sick, with analysts upping their price targets at will. 50, 75, 100 times earnings, who cares!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News